In clinical practice, IHC markers are used to discern the COO subtypes of DLBCL (e.g., CD10, BCL6, and MUM1 in the Hans algorithm), as well as DEL status (MYC and BCL2) (4, 9). Here, IRF4 is linked to diffuse large B-cell lymphoma.